Literature DB >> 27714504

Diabetic charcot neuroarthropathy: prevalence, demographics and outcome in a regional referral centre.

A O'Loughlin1, E Kellegher2, C McCusker2, R Canavan3.   

Abstract

BACKGROUND: Diabetic Charcot neuroarthropathy (DCN) is a devastating complication for people with diabetes mellitus. The failure to diagnose DCN and institute treatment in the acute phase leads to permanent deformity and significant morbidity. There is a paucity of data on the prevalence and characteristics of patients who have developed this complication of diabetes. AIMS: To determine the prevalence, clinical characteristics and outcomes of patients with DCN from 2006 to 2012.
METHODS: Case finding was performed by searching three independent lists for the period 2006-2012 including: SYNGO radiology database, HIPE database of hospital discharges, and, combined list from podiatry, endocrinology, vascular surgery and orthopaedic clinics. A consensus meeting with chart review was undertaken to confirm diagnosis of DCN. A proforma was completed from chart review to determine clinical characteristics, initial treatment and outcomes for patients with DCN.
RESULTS: Forty cases of DCN were identified, resulting in an estimated period prevalence of 0.3 %. The majority of patients were male (68 %); most patients had T2DM (73 %). Mean ± SD for age was 58 ± 10 years and mean duration of diabetes was 15 ± 9 years. In the acute phase of DCN, offloading was performed in 50 %. Bisphosphonates were administered to 5 % and surgery undertaken in 5 % of cases. 38 % of patients developed subsequent foot ulceration and 20 % required amputation.
CONCLUSIONS: This is the first prevalence estimate of DCN in Ireland. These data suggest diagnosis of DCN is missed in the acute phase. There exists a significant risk of diabetic foot ulceration and amputation with DCN.

Entities:  

Keywords:  Amputation; Charcot; Diabetes mellitus; Neuroarthropathy; Ulceration

Mesh:

Year:  2016        PMID: 27714504     DOI: 10.1007/s11845-016-1508-5

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  9 in total

1.  Audit of acute Charcot's disease in the UK: the CDUK study.

Authors:  F L Game; R Catlow; G R Jones; M E Edmonds; E B Jude; G Rayman; W J Jeffcoate
Journal:  Diabetologia       Date:  2011-11-08       Impact factor: 10.122

2.  Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial.

Authors:  Dario Pitocco; Valeria Ruotolo; Salvatore Caputo; Lorena Mancini; Chiara M Collina; Andrea Manto; Paolo Caradonna; Giovanni Ghirlanda
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

Review 3.  The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes.

Authors:  William J Jeffcoate; Fran Game; Peter R Cavanagh
Journal:  Lancet       Date:  2005-08-10       Impact factor: 79.321

4.  Reducing major lower extremity amputations after the introduction of a multidisciplinary team for the diabetic foot.

Authors:  José Antonio Rubio; Javier Aragón-Sánchez; Sara Jiménez; Gregorio Guadalix; Agustín Albarracín; Carmen Salido; José Sanz-Moreno; Fernando Ruiz-Grande; Nuria Gil-Fournier; Julia Álvarez
Journal:  Int J Low Extrem Wounds       Date:  2014-03       Impact factor: 2.057

Review 5.  Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature.

Authors:  J-L Richard; M Almasri; S Schuldiner
Journal:  Diabetologia       Date:  2012-02-25       Impact factor: 10.122

6.  Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.

Authors:  E B Jude; P L Selby; J Burgess; P Lilleystone; E B Mawer; S R Page; M Donohoe; A V Foster; M E Edmonds; A J Boulton
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

7.  Charcot osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice.

Authors:  Evanthia Gouveri; Nikolaos Papanas
Journal:  World J Diabetes       Date:  2011-05-15

8.  Bisphosphonates for the treatment of Charcot neuroarthropathy.

Authors:  John J Anderson; Kirk E Woelffer; John J Holtzman; Allen M Jacobs
Journal:  J Foot Ankle Surg       Date:  2004 Sep-Oct       Impact factor: 1.286

9.  The Charcot foot in diabetes.

Authors:  Lee C Rogers; Robert G Frykberg; David G Armstrong; Andrew J M Boulton; Michael Edmonds; Georges Ha Van; Agnes Hartemann; Frances Game; William Jeffcoate; Alexandra Jirkovska; Edward Jude; Stephan Morbach; William B Morrison; Michael Pinzur; Dario Pitocco; Lee Sanders; Dane K Wukich; Luigi Uccioli
Journal:  Diabetes Care       Date:  2011-09       Impact factor: 19.112

  9 in total
  5 in total

1.  Acute hot foot: Charcot neuroarthropathy or osteomyelitis? Untangling a diagnostic web.

Authors:  Louise Goldsmith; Matthew Barlow; Paul Jeffrey Evans; Upendram Srinivas-Shankar
Journal:  BMJ Case Rep       Date:  2019-05-13

2.  Physician knowledge of a rare foot condition - influence of diabetic patient population on self-described knowledge and treatment.

Authors:  Brian M Schmidt; James S Wrobel; Crystal M Holmes
Journal:  Clin Diabetes Endocrinol       Date:  2017-02-08

Review 3.  Factors impacting the evidence-based assessment, diagnosis and management of Acute Charcot Neuroarthropathy: a systematic review.

Authors:  D Diacogiorgis; B M Perrin; M I C Kingsley
Journal:  J Foot Ankle Res       Date:  2021-04-07       Impact factor: 2.303

4.  Charcot neuroarthropathy patient education among podiatrists in Scotland: a modified Delphi approach.

Authors:  Benjamin Bullen; Matthew Young; Carla McArdle; Mairghread Ellis
Journal:  J Foot Ankle Res       Date:  2018-09-24       Impact factor: 2.303

5.  Long-term follow-up of conservative treatment of Charcot feet.

Authors:  Viviane Gratwohl; Thorsten Jentzsch; Madlaina Schöni; Dominik Kaiser; Martin C Berli; Thomas Böni; Felix W A Waibel
Journal:  Arch Orthop Trauma Surg       Date:  2021-04-07       Impact factor: 2.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.